Cullinan to launch registrational Phase 2 CLN-049 trial in relapsed/refractory AML in Q3 2026

• Cullinan Therapeutics will launch a potentially registrational Phase 2 trial of CLN-049 in relapsed/refractory AML in Q3 2026.
• The plan follows positive FDA End-of-Phase 1 feedback, supporting a streamlined Phase 2 design aimed at defining dose then moving into a single-arm cohort.
• Early results were previously presented at the 2025 ASH meeting, showing encouraging activity with a generally favorable safety profile.
• An update from the ongoing dose-escalation study is scheduled for Q4 2026.
• A separate Phase 1/2 combination study in previously untreated AML is also set to begin, pairing CLN-049 with standard therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.